Sofosbuvir plus ribavirin with or without peginterferon for the treatment of hepatitis C virus: Results from a phase 3b study in China.
Lai WeiQing XieJin Lin HouJidong JiaWu LiMin XuJun LiShanming WuJun ChengJianning JiangGuiqiang WangYongfeng YangZhuangbo MouZhi Liang GaoGuozhong GongJun Qi NiuPeng HuHong TangFeng LinXiaoguang DouLanjuan LiLun Li ZhangYuemin NanBenedetta MassettoJenny C YangSteven J KnoxKathryn KerseyPolina GermanHongmei MoDeyuan JiangDiana M BrainardJiaji JiangQin NingZhongping DuanPublished in: Journal of gastroenterology and hepatology (2018)
Sofosbuvir-based regimens were highly effective and safe in Chinese patients with HCV genotype 1, 2, 3, or 6, suggesting sofosbuvir could serve as the backbone for HCV treatment in China irrespective of genotype.